Literature DB >> 29336624

Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.

Habib Zarredar1,2, Khalil Ansarin1, Behzad Baradaran3, Shiva Ahdi Khosroshahi4, Safar Farajnia1,4.   

Abstract

Lung cancer is the leading cause of cancer-related mortality with about 1.6 million deaths every year worldwide. Gene mutations and overexpression of oncogenes play a central role in malignant transformation in NSCLC. Conventional approaches for treatments of NSCLC have shown low levels of success while showing severe side effects. Target therapy using siRNA has recently emerged as a new strategy for cancer treatment by specific targeting of genes involved in the development and metastasis of cancer. This article dedicated to an update review of molecular targets could potentially be used for target therapy of lung cancer using SiRNA technology.

Entities:  

Keywords:  EGFR; KRAS; Non-small-cell lung cancer; Target therapy; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29336624     DOI: 10.1080/07357907.2017.1416393

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

1.  Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.

Authors:  Dongfang Tang; Yu Chen Zhao; Danwen Qian; Hongliang Liu; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Carolyn Glass; Wen Gao; Qingyi Wei
Journal:  Mol Carcinog       Date:  2019-11-12       Impact factor: 5.139

2.  Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line.

Authors:  Shiva Kamran; Ensiyeh Seyedrezazadeh; Dariush Shanehbandi; Milad Asadi; Venus Zafari; Najibeh Shekari; Leila Namvar; Habib Zarredar
Journal:  J Gastrointest Cancer       Date:  2021-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.